Comparison of Extracorporeal Shock Wave Lithotripsy (ESWL) and Ultra-mini Percutaneous Nephrolithotomy (PCNI), in Renal Stones <20 mm.

May 20, 2026 updated by: Muhammad Aamir Latif

Comparison of the Outcome of Extracorporeal Shock Wave Lithotripsy (ESWL) and Ultra-mini Percutaneous Nephrolithotomy (PCNL), in Renal Stones <20 mm.

There is a dearth of information comparing ultra-mini PNCL with ESWI in Pakistan for kidney stones smaller than 20 mm. Hence the current study was planned with the objective of comparing the outcome of ESWL and ultra-mini PCNL in renal stones less than 20 mm.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Even though small PCNL and ESWL are tried-and-true techniques for kidney calculus, their usage poses unique challenges since they need precision to guarantee effective stone removal while minimizing invasiveness. Despite these advantages, selecting the optimum course of action is challenging due to risks of both modalities. The results of this investigation would therefore help to improve the treatment of the patients with renal proximal stones that are smaller than 20 mm.

Study Type

Interventional

Enrollment (Actual)

138

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab Province
      • Bahawalpur, Punjab Province, Pakistan, 63100
        • Bahawal Victoria Hospital/Quaid-e-Azam Medical College

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients of any gender
  • Aged 20-60 years
  • With a single kidney stone in renal pelvis smaller than 20 mm

Exclusion Criteria:

  • Pregnancy
  • Hemorrhage problems
  • Sepsis and pyonephrosis
  • With pelvic kidneys
  • Obstruction of the pelvi-ureteric junction
  • Chronic illness (chronic liver disease, chronic renal failure, chronic drug use)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group-A
Patients were treated with ultra-mini PCNL with double J stent implantation.
Procedure: Ultra-mini PCNL
Patients were treated with ultra-mini PCNL with DJ stent implantation.
Experimental: Group-B
Extracorporeal shock wave lithotripsy (ESWL) with double J stent implantation was performed in patients. Typically, the therapy began with a lower power of 1 kilovolt (kV) and was progressively increased to 20 kV. Each session included no more than 2000 shocks.
Procedure: Extracorporeal shock wave lithotripsy
Extracorporeal shock wave lithotripsy (ESWL) with DJ stent implantation was performed in patients. Typically, the therapy began with a lower power of 1 kV and was progressively increased to 20 kV. Each session included no more than 2000 shocks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stone clearance
Time Frame: 4 weeks
The frequency of the patients with full stone clearance was noted and cmpared between the groups.
4 weeks
Urinary tract infection
Time Frame: 4 weeks
The frequency of patients reported with urinary tract infection was noted and compared between the groups.
4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Muhammad Aamir Latif

Investigators

  • Principal Investigator: Muhammad Saleem, Bahawal Victoria Hospital/Quid-e-Azam Medical College, Bahawalpur
  • Study Director: Mumtaz Rasool, FCPS, Bahawal Victoria Hospital/Quaid-e-Azam Medical College, Bahawalpur

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2025

Primary Completion (Actual)

December 31, 2025

Study Completion (Actual)

December 31, 2025

Study Registration Dates

First Submitted

May 20, 2026

First Submitted That Met QC Criteria

May 20, 2026

First Posted (Actual)

May 27, 2026

Study Record Updates

Last Update Posted (Actual)

May 27, 2026

Last Update Submitted That Met QC Criteria

May 20, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Dr-Saleem-BVH

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Data can be shared on a reasonable request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Renal Calculi

Clinical Trials on Ultra-mini PCNL

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe